Effect of sacubitril/valsartan on brain natriuretic peptide level and prognosis of acute cerebral infarction

• Published in: PloS one 2023-09, Vol.18 (9), p.e0291754-e0291754
• Main Authors: Shen, Xiaozhu, Gong, Chen, Liu, Mengqian, Jiang, Yi, Xu, Yiwen, Ge, Zhonglin, Tao, Zhonghai, Dong, Nan, Liao, Juan, Yu, Liqiang, Fang, Qi
• Format: Article
• Language: English
• Subjects: Angiotensin; Antihypertensives; Biology and Life Sciences; Blood pressure; Brain; Brain natriuretic peptide; Brain-derived neurotrophic factor; Cardiac arrhythmia; Care and treatment; Cerebral infarction; Cerebral ischemia; Cholesterol; Complications and side effects; Health aspects; Hemoglobin; Hemorrhage; Homeostasis; Hospitals; Hypertension; Hypotension; Infarction; Ischemia; Laws, regulations and rules; Medical prognosis; Medicine and Health Sciences; Natriuretic peptides; Neprilysin; Neuroprotection; Patient outcomes; Patients; Peptides; Plasma; Plasma levels; Prognosis; Randomization; Renin; Research and Analysis Methods; Software; Stroke; Valsartan; Veins & arteries
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0291754

Previous studies demonstrated that elevated brain natriuretic peptide (BNP) level is associated with adverse clinical outcomes of acute cerebral infarction (ACI). Researchers hypothesized that BNP might be a potential neuroprotective factor against cerebral ischemia because of the antagonistic effect of the natriuretic peptide system on the renin-angiotensin system and regulation of cardiovascular homeostasis. However, whether decreasing the BNP level can improve the prognosis of ACI has not been studied yet. The main effect of sacubitril/valsartan is to enhance the natriuretic peptide system. We investigated whether the intervention of plasma BNP levels with sacubitril/valsartan could improve the prognosis of patients with ACI. In a randomized, controlled, parallel-group trial of patients with ACI within 48 hours of symptom onset and need for antihypertensive therapy, patients have randomized within 24 hours to sacubitril/valsartan 200mg once daily (the intervention group) or to conventional medical medication (the control group). The primary outcome was a change in plasma BNP levels before and after sacubitril/valsartan administration. The secondary outcomes included plasma levels of brain-derived neurotrophic factor (BDNF), Corin and neprilysin (NEP) before and after medication, the modified Rankin scale, and the National Institutes of Health Stroke Scale (at onset, at discharge, 30 days, and 90 days after discharge). We evaluated 80 eligible patients admitted to the Stroke Center of Lianyungang Second People's Hospital between 1st May, 2021 and 31st June, 2022. Except for 28 patients excluded before randomization and 14 patients who did not meet the criteria or dropped out or lost to follow-up during the trial, the remaining 38 patients (intervention group: 17, control group: 21) had well-balanced baseline features. In this trial, we found that plasma BNP levels (P = 0.003) decreased and NEP levels (P = 0.006) increased in enrolled patients after treatment with sacubitril/valsartan. There were no differences in plasma BDNF and Corin levels between the two groups. Furthermore, no difference in functional prognosis was observed between the two groups (all P values>0.05). Sacubitril/valsartan reduced endogenous plasma BNP levels in patients with ACI and did not affect their short-term prognosis.